Evaluation of ALT-2074 in Subjects With Type-2 Diabetes, Haptoglobin Type 2-2 Genotype and Coronary Artery Disease
Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
ALT-2074 (BXT-51072) belongs to a class of drugs called "glutathione peroxidase mimics."
ALT-2074 works by imitating a substance produced in various tissues in the body, which
prevents damage of the heart and blood vessels. Diabetic patients with a haptoglobin 2-2
genotype have poor cardiovascular clinical outcomes.
The purpose of this study is to assess the safety, the pharmacokinetic profile and
characterize the effect on biomarkers of inflammation and oxidative stress of repeat doses of
ALT 2074. Subjects must be diabetic, with evidence of coronary artery disease and a
haptoglobin 2-2 genotype